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Abstract
Background Oral semaglutide was approved in 2019 for blood glucose control in patients with type 2 diabetes mellitus 
(T2DM) and was the first oral glucagon-like peptide 1 receptor agonist (GLP-1 RA). T2DM is associated with substantial 
healthcare expenditures in the US, so the cost of a new intervention should be weighed against clinical benefits.
Objective This study evaluated the budget impact of a treatment pathway with oral semaglutide 14 mg daily versus oral sitag-
liptin 100 mg daily among patients not achieving target glycated hemoglobin (HbA1c) level despite treatment with metformin.
Methods This study used the validated IQVIA™ CORE Diabetes Model to simulate the treatment impact of oral semaglu-
tide 14 mg and sitagliptin 100 mg over a 5-year time horizon from a US healthcare sector (payer) perspective. Trial data 
(PIONEER 3) informed cohort characteristics and treatment effects, and literature sources informed event costs. Population 
and market share data were from the literature and data on file. The analysis evaluated the estimated budget impact of oral 
semaglutide 14 mg use for patients currently using sitagliptin 100 mg considering both direct medical and treatment costs 
to understand the impact on total cost of care, given underlying treatment performance and impact on avoidable events.
Results In a hypothetical plan of 1 million lives, an estimated 1993 patients were treated with sitagliptin 100 mg in the target 
population. Following these patients over 5 years, the incremental direct medical and treatment costs of a patient using oral 
semaglutide 14 mg versus sitagliptin 100 mg was $US16,562, a 70.7% increase (year 2019 values). A hypothetical payer 
would spend an additional $US3,300,143 (7.1%) over 5 years for every 10% of market share that oral semaglutide 14 mg 
takes away from sitagliptin 100 mg. Univariate and scenario analyses with alternate inputs and assumptions demonstrated 
consistent results.
Conclusions Use of oral semaglutide 14 mg in patients currently receiving sitagliptin 100 mg substantially increases the 
budget impact for patients with T2DM whose blood glucose level is not controlled with metformin over a 5-year time horizon 
for US healthcare payers.
Plain Language Summary
Patients with type 2 diabetes mellitus (T2DM) have many treatment options. Choices depend on factors such as cost, prefer-
ence, and patient characteristics. Oral semaglutide was recently approved for the treatment of T2DM as the first oral therapy 
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of its class. This study estimated the cost for patients treated with sitagliptin 100 mg, a commonly used T2DM treatment, 
versus oral semaglutide 14 mg for patients whose disease is not well controlled with metformin. Costs and effects were 
estimated over 5 years for each treatment strategy using predictive model equations and clinical trial data for the two treat-
ments. These costs were considered for both a hypothetical healthcare plan of 1 million lives and the full US population. A 
patient treated with oral semaglutide 14 mg would expect to see 70.7% higher costs than a patient treated with sitagliptin 
100 mg over 5 years. For every 10% of patients who would switch from sitagliptin 100 mg to oral semaglutide 14 mg, costs 
would increase by 7.1%. Changing the cost of oral semaglutide 14 mg had the greatest impact on model results. The find-
ings from the analysis were consistent across a range of alternate model inputs. Oral semaglutide 14 mg is more costly than 
sitagliptin 100 mg over 5 years.
Key Points for Decision Makers 
Using clinical projections via the validated IQVIA™ 
CORE Diabetes Model in combination with a budget 
impact modeling approach, this study integrates informa-
tion on how two oral products affect the patient journey 
in diabetes into an over-arching assessment of budget 
impact to understand the total cost-of-care implications 
for formulary decisions.
Over a 5-year time horizon, oral semaglutide 14 mg was 
a more costly treatment strategy than sitagliptin 100 mg.
1 Introduction
Type 2 diabetes mellitus (T2DM) is a multifactorial disease 
characterized by an increased risk of obesity, macrovascular 
conditions such as cardiovascular disease, and microvascu-
lar disease that can lead to kidney failure, neuropathy, and 
blindness [1]. The latest report from the Centers for Disease 
Control and Prevention found that diabetes affected 30.3 
million people in the USA in 2015, with 90–95% of these 
having T2DM [2]. This corresponds to a prevalence of diag-
nosed T2DM in the USA in 2016 of 8.6%, or 21.0 million 
adults [3]. In addition to increased morbidity, mortality is 
higher for people with diabetes than for those without, and 
diabetes is among the leading causes of death in the USA, 
resulting in 252,806 (9.3%) deaths in 2015 [2]. Diabetes is 
also the primary contributor to cardiovascular death, the top 
cause of death in the USA [4, 5].
The high prevalence and risk of complications/comor-
bidities associated with T2DM leads to a large economic 
burden on patients, the population, and health systems. 
Undiscounted diabetes medication spending in the USA 
increased from $US33.7 billion in 2014 to 53.7 billion in 
2017 [6]. The direct and indirect costs for people with diabe-
tes account for about a quarter of healthcare dollars spent in 
the USA, with a total cost of diagnosed diabetes in 2017 of 
$US327 billion [7]. Care for a person with diabetes costs an 
average of $US16,752 per year [7, 8]. Among annual expen-
ditures, hospitalization is a key driver of costs in patients 
with T2DM. A retrospective cohort analysis showed the 
mean 12-month all-cause medical costs to be $US9624 for 
patients not incurring a hospitalization, $US42,011 for those 
with an inpatient admission but no 30-day readmission, and 
$US76,806 for patients with both an inpatient admission and 
30-day readmission [9].
The key goal of diabetes management is to achieve glyce-
mic control, which subsequently lowers the risk of compli-
cations, including cardiovascular protection, and improves 
quality of life [10, 11]. The 2020 American Diabetes Asso-
ciation standards of care recommend a glycated hemoglobin 
(HbA1c) target of 6.5–8%, depending on patient character-
istics and history of hypoglycemia and adverse effects. A 
treatment switch threshold of 8% may be appropriate for 
patients with a history of severe hypoglycemia, limited life 
expectancy, or advanced cardiovascular complications for 
whom previous glucose-lowering agents have failed [10]. 
However, treatment switches at higher HbA1c values have 
been observed in the real-world setting. A study of more 
than 7000 patients with uncontrolled T2DM identified 44% 
of patients not switching treatments at an HbA1c of 9% or 
even higher [12, 13].
Metformin is the preferred initial pharmacologic agent 
for patients diagnosed with T2DM whose HbA1c level is 
uncontrolled with lifestyle changes. If treatment goals are 
not met, further intensification should not be delayed [10]. 
In choosing add-on pharmacologic agents, a patient-centered 
approach is recommended that incorporates considerations 
for comorbidities, hypoglycemia risk, impact on weight, 
cost, risk of side effects, and patient preference [10]. In 
addition, the European Society of Cardiology also empha-
sizes a multifactorial management approach that integrates 
reduction in HbA1c, systolic blood pressure (SBP), and 
lipids, which decreases cardiovascular events [11]. Dipep-
tidyl peptidase-4 inhibitors (DPP-4i) are effective in lower-
ing HbA1c without increasing the risk of hypoglycemia or 
cardiovascular events [14, 15]. Compounds with evidence 
to reduce cardiovascular events include sodium glucose 
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cotransporter-2 inhibitors (SGLT-2i) and glucagon-like 
peptide-1 receptor agonists (GLP-1 RA), which are cur-
rently recommended as first-line therapy for patients with 
high cardiovascular risk, including nephropathy [10]. Yet, 
the oral formulation of semaglutide (a GLP-1 RA) failed 
to show an additional cardiovascular event reduction when 
tested versus the antihyperglycemic standard of care in a 
population of patients with T2DM and at high cardiovascu-
lar risk [16]. Other recommended T2DM therapies include 
sulfonylureas and thiazolidinedione, especially if cost is an 
issue [10]. A recent US study showed that sulfonylureas and 
DPP-4i were the most common second antidiabetic add-on 
treatment (46 and 20%, respectively) [17]. However, the use 
of sulfonylureas and thiazolidinedione has decreased over 
time, whereas the use of DPP-4i has increased from 6.2% in 
2008 to 12.4% in 2015 [18].
With oral semaglutide being the first oral GLP-1 RA 
available to patients with T2DM, it is important to under-
stand the comparative performance beyond the trial, includ-
ing the impact on patients’ risk for avoidable events and total 
cost of care [19]. Comparative value assessments are needed 
to provide a more comprehensive picture of incremental 
value and inform healthcare decision making and resource 
allocation across healthcare systems. Oral semaglutide 
(3 mg, 7 mg, and 14 mg) has been directly compared with 
relevant doses of empagliflozin, sitagliptin, and liraglutide 
in clinical trials with patients with T2DM uncontrolled with 
metformin, sulfonylureas, and/or SGLT-2i [20–23]. In the 
clinical trials PIONEER 3 and PIONEER 7, oral semaglutide 
14 mg statistically significantly reduced HbA1c compared 
with sitagliptin 100 mg (PIONEER 3: − 1.3% oral semaglu-
tide 14 mg vs. − 0.8% sitagliptin over 26 weeks; PIONEER 
7: − 1.3% oral semaglutide flexible dose vs. − 0.8% sitaglip-
tin over 52 weeks) [22, 23]. To date, a budget impact assess-
ment on the impact of oral semaglutide 14 mg for patients 
for whom metformin fails in the USA is lacking.
As new T2DM treatments displace current therapies, it 
is important to consider the financial impact of this trade-
off. Sitagliptin 100 mg was selected as the comparator of 
interest because it has the same oral mode of administration 
and head-to-head evidence versus oral semaglutide 14 mg is 
available. Manufacturer data on file and the literature indi-
cate that DPP-4i are commonly used as second-line treat-
ments, and sitagliptin 100 mg represents the majority of 
DPP-4i use [17]. A budget-impact analysis was conducted 
to understand the total direct medical cost tradeoff associ-
ated with switching patients from sitagliptin 100 mg to oral 
semaglutide 14 mg in second-line T2DM from a healthcare 
sector perspective.
2  Methods
2.1  Budget‑Impact Model (BIM) Framework
This budget-impact model (BIM) used a comparative cost 
determination framework to compare patients currently 
treated with sitagliptin 100 mg and patients with oral sema-
glutide 14 mg uptake. The analysis utilized the IQVIA™ 
Core Diabetes Model (CDM) v9.0 to estimate clinical out-
comes and direct medical costs to allow for estimation of 
budget impact and total cost of care given relative clinical 
performance. The output from the CDM was incorporated 
into the BIM, which considered the number of patients 
Fig. 1  Model structure. This figure displays how the CDM incorporates clinical outcomes (e.g. costs, events, mortality), which feed into the 
underlying BIM structure to produce the budget impact analysis results. BIM budget impact model, CDM Core Diabetes Model
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currently receiving sitagliptin 100 mg for uncontrolled blood 
glucose on metformin and the financial impact of new oral 
semaglutide 14 mg use in this population. Patients were 
allowed to exit the cohort because of mortality based on the 
CDM output (Fig. 1).
2.2  IQVIA™ Core Diabetes Model (CDM)
The IQVIA™ CDM is an internet application that can 
assess the long-term clinical and cost impacts of diabetes 
interventions. The model includes 17 sub-models for dia-
betes complications using a combination of semi-Markov 
structures and Monte Carlo simulations, which uses data 
on HbA1c and other physiological impacts to predict events 
over time. Information on the model has been extensively 
published, along with robust validation exercises, including 
internal and external validation [24–26]. This analysis used 
the most recently published UKPDS (UK Prospective Dia-
betes Study) T2DM risk equations for HbA1c progression 
and mortality (UKPDS82), a long-term follow up of a large 
patient cohort of patients with T2DM [27]. Simulations were 
run for 5 years to reflect the recommended time horizon for 
BIMs, using a theoretical cohort of 1000 patients run for 
1000 simulations [28]. Costs were reported in $US, year 
2019 values, and no discounting was included, based on best 
practices [28].
2.3  Model Inputs: CDM
2.3.1  Baseline Characteristics
The PIONEER 3 study provided a head-to-head compari-
son of oral semaglutide (3 mg, 7 mg, and 14 mg) versus 
sitagliptin 100 mg in adults with T2DM uncontrolled under 
metformin [22]. The model cohort used the patient char-
acteristics reported in PIONEER 3, a weighted average 
across treatment arms, aligning with the population from 
which clinical efficacy was derived for both oral semaglu-
tide and sitagliptin. Patient characteristics required by the 
CDM but not available from the PIONEER 3 publication 
were informed by the VERTIS FACTORIAL study, which 
investigated the efficacy of sitagliptin + ertugliflozin versus 
each compound individually upon metformin failure [29]. 
The overlapping baseline characteristics between these two 
studies were generally consistent and appropriate for patients 
at this line of therapy. Key baseline characteristics are pre-
sented in Table 1, with full data available in Table 1 in the 
electronic supplementary material (ESM).
2.3.2  Intervention Effects
The base-case analysis compared two treatment pathways for 
the target population (Fig. 1 in the ESM). Patients in treat-
ment pathway 1 initiated treatment with oral semaglutide 
Table 1  Key cohort and 
treatment cost inputs
BMI body mass index, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, HbA1c 
glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein choles-
terol, SBP systolic blood pressure, TC total cholesterol, TG triglycerides
Characteristics Value Reference
Baseline characteristics
 Start age, years 57.75 [22]
 Duration of diabetes, years 8.55 [22]
 % Male 52.8 [22]
 HbA1c, % 8.33 [22]
 SBP, mmHg 134.00 [22]
 DBP, mmHg 80.50 [22]
 TC, mg/dL 173.42 [22]
 HDL-C, mg/dL 44.53 [22]
 LDL-C, mg/dL 92.26 [22]
 TG, mg/dL 156.26 [22]
 BMI, kg/m2 32.50 [22]
 eGFR, mL/min/1.73  m2 95.75 [22]
Annual treatment costs; $US, year 2019 values
 Metformin + oral semaglutide 6110.99 [22, 34, 35]
 Metformin + oral semaglutide + insulin glargine 11,391.15 [30, 31, 34, 35]
 Metformin + sitagliptin 1586.76 [22, 34, 35]
 Metformin + sitagliptin + insulin glargine 6866.92 [30, 34, 35]
 Metformin + insulin glargine + bolus insulin 8399.04 [22, 30, 34, 37]
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14 mg on top of background metformin (metformin + oral 
semaglutide 14 mg), and patients in pathway 2 initiated sit-
agliptin 100 mg treatment on top of background metformin 
(metformin + sitagliptin 100 mg). The treatment effect for 
each arm was informed by the PIONEER 3 study and was 
applied upon model initiation [22] (Table 2).
When patients’ HbA1c exceeded 8%, basal insulin (insu-
lin glargine) was added to the initial treatment (Pathway 
1: metformin + oral semaglutide 14 mg + insulin glargine; 
Pathway 2: metformin + sitagliptin 100 mg + insulin glar-
gine). The effect of metformin + sitagliptin 100 mg + insulin 
glargine was based on the intervention arm of the CompoSIT 
I study [30] (Table 2). Data for the treatment effect of insu-
lin glargine when added to metformin + oral semaglutide 
14 mg were limited. The PIONEER 8 study [31] reported 
the HbA1c and hypoglycemia rate of oral semaglutide 14 mg 
when used with insulin. HbA1c from this study was used 
for the insulin glargine step for the oral semaglutide 14 mg 
pathway. The definition of hypoglycemic events differed 
between CompoSIT I and PIONEER 8. Additionally, when 
mapping the PIONEER 8 data to fields in the CDM, the 
event rate derived was notably higher than when using Com-
poSIT I. To be conservative, and given the expectation that 
hypoglycemic events should not be notably different, the 
hypoglycemia rates from CompoSIT I were used for met-
formin + oral semaglutide 14 mg + insulin glargine. Other 
missing parameters from PIONEER 8 were assumed equal 
to those from CompoSIT I.
A scenario analysis has patients switch treatments more 
quickly when patients’ HbA1c exceeded the threshold of 
7%. In this case, patients add bolus insulin while dropping 
the primary therapy (e.g., oral semaglutide or sitagliptin). 
Efficacy of metformin + insulin glargine + bolus insulin was 
based on the DUAL VII study and the GINGER study [32, 
33] (Table 2).
Treatment effects on cardiovascular outcomes beyond 
predictions from the model risk equations were excluded 
from the base case for several reasons: (1) cardiovascular 
outcomes trials (CVOTs) for both oral semaglutide 14 mg 
and sitagliptin 100 mg showed nonsignificant treatment 
effects in established cardiovascular populations; (2) CVOT 
populations were distinctly different from the PIONEER 3 
population; (3) these effects were not studied in head-to-
head trials [15, 16]. However, the impact of treatment on 
cardiovascular outcomes are implicitly captured within the 
risk equations used in the CDM. In addition, a scenario 
analysis tests the point estimates of the hazard ratios for 
cardiovascular events relative to placebo for the initial step 
in therapy from the CVOT studies.
Table 2  Treatment effect
BMI body mass index, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, HbA1c glycated hemoglobin, HDL-C high-den-
sity lipoprotein cholesterol, IG insulin glargine, LDL-C low-density lipoprotein cholesterol, MET metformin, NSHE non-severe hypoglycemic 
event, SBP systolic blood pressure, SEM semaglutide, SHE severe hypoglycemic event, SIT sitagliptin, TC total cholesterol, TG triglycerides
a Treatments used in scenario analyses
Therapy Primary intervention Insulin glargine Insulin glar-
gine + bolus
MET + oral 
SEM 14 mg 
[22]




 SEMa [22, 23]
MET + oral SEM 
14 mg + IG [30, 
31]
MET + SIT 
100 mg + IG 
[30, 31]
MET + IGa [30, 
31]
MET + IG + bolus 
 insulina [32, 33]
HbA1c, %  − 1.300  − 0.800  − 1.142  − 1.300  − 1.880  − 1.420  − 1.500
SBP, mmHg  − 3.000  − 2.000  − 2.820  − 0.440  − 0.440 0.590 0.000
DBP, mmHg  − 1.000 0.000  − 1.000  − 0.303  − 0.303  − 0.870 0.000
TC, mg/dL  − 5.196 0.000  − 4.193  − 2.280  − 2.280  − 1.760 0.000
LDL-C, mg/dL  − 1.837 1.863  − 1.216  − 0.536  − 0.536 0.167 0.000
HDL-C, mg/dL  − 0.898  − 0.444  − 0.794 1.280 1.280 1.450 0.000
TG, mg/dL  − 12.522  − 4.701  − 9.553  − 18.250  − 18.250  − 20.270 0.000
BMI, kg/m2  − 1.100  − 0.200  − 0.942 0.560 0.560 0.620 1.270
eGFR, mL/
min/1.73  m2
 − 1.900  − 2.880  − 1.822 1.430 1.430 0.540 0.000
NSHE 40.860 31.330 38.764 145.430 145.430 180.660 784.430
SHE, non-medical 
assistance
15.054 15.021 13.099 9.110 9.110 31.340 0.000
SHE, medical 
assistance
0.430 1.717 0.255 0.460 0.460 0.000 0.000
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2.3.3  Costs
Unit costs of treatments were based on wholesale acquisition 
costs (WAC) from the MediSpan PriceRx database, using the 
least expensive option if multiple forms were available [34]. 
Net costs of oral semaglutide 14 mg and sitagliptin 100 mg 
were used to reflect cost of drugs in practice, assumed to be 
a 35.1% discount for oral semaglutide 14 mg (based on the 
discount for injectable semaglutide) and a 72.6% discount 
for sitagliptin 100 mg based on the recently published Insti-
tute for Clinical and Economic Review assessment of oral 
semaglutide [35].
Dosing for each regimen reflects the prescribing informa-
tion, except for insulin, which is patient specific [36]. The 
daily insulin glargine dose of 53.2 IU/day was applied when 
insulin glargine was used in combination with sitagliptin 
100 mg, based on the intervention arm of CompoSIT I [30]. 
Given that this dose is similar to the baseline insulin dose 
(54 IU/day) in PIONEER 8, the same dose was applied to 
the metformin + oral semaglutide 14 mg + insulin glargine 
combination. In a scenario analysis, a daily insulin glargine 
dose of 61.3 IU/day was applied when insulin glargine was 
used with bolus insulin, based on the comparator arm of 
CompoSIT I [30]. Dosage for bolus insulin (represented by 
insulin aspart) was calculated assuming 0.2 units/kg [37] 
and the average patient weight derived from PIONEER 3 
(18.2 IU/day) [22].
Costs of test strips, lancets, and needles were considered 
for insulin regimens. Patients on insulin regimens were 
assumed to use one lancet and 2.7 test strips per day, with 
those on insulin glargine + bolus insulin requiring an addi-
tional two needles [38]. Unit costs were sourced from the 
ADW website [39] and the Centers for Medicaid and Medi-
care Services durable medical equipment file [40].
Dosing, unit cost, and resource use were combined to 
generate annual costs for each treatment (Table 1). T2DM 
management costs were based on the literature, PriceRx, and 
Medicare fee schedules [34, 41–45] (Table 2 in the ESM).
2.4  Model Inputs—BIM
2.4.1  Population
The budget-impact analysis considered the number of 
patients who would be eligible for oral semaglutide 14 mg 
in the second-line T2DM population. A hypothetical plan 
size of 1 million lives was assumed, and the following steps 
were applied to arrive at the eligible population: propor-
tion of the population who are adults (77.8%), T2DM 
prevalence among adults in the USA (8.6%), proportion of 
patients with T2DM who receive metformin (41.0%), and 
proportion for whom metformin has failed (48.0%) [17, 
46–48]. A scenario analysis considered the full US popula-
tion, estimated at 332,639,000 for the year 2020, with the 
same steps applied in a top-down population cascade [46] 
(Table 3).
2.4.2  Market Shares
A recent retrospective database analysis found that 20% of 
second-line patients with T2DM used DPP-4i [17]. Based 
on manufacturer data on file, sitagliptin 100 mg represents 
75.7% of the overall DPP-4i utilization in the USA. Uptake 
assumptions for oral semaglutide 14 mg included 14%, 25%, 
50%, 75%, and 100% of the current sitagliptin 100 mg share 
[35].
2.5  Scenario Analyses
Scenario analyses were performed with alternative input 
values and assumptions to assess the robustness of model 
results given underlying uncertainty, including weighted 
dose-specific oral semaglutide treatment effect using the 
dose distribution from the PIONEER 7 trial [23], using 
alternative assumptions for the metformin + oral sema-
glutide 14 mg + insulin glargine step, varying the oral 
semaglutide 14 mg price, incorporating different therapy 
Table 3  Population inputs
DPP-4i dipeptidyl peptidase-4 inhibitor, T2DM type 2 diabetes mellitus
a Amounts may not sum because of rounding
Input % Hypothetical  plana US  populationa References
Total population 1,000,000 332,639,000 [46]
Percentage adults 77.8 777,648 258,676,000 [46]
T2DM prevalence 8.6 66,878 22,246,136 [47]
Percentage treated with metformin 41.0 27,420 9,120,916 [48]
Percentage failed metformin therapy 48.0 13,162 4,378,040 [17]
Percentage treated with DPP-4i 20.0 2623 875,608 [17]
Percentage receiving sitagliptin 75.7 1993 662,835 Manufac-
turer data 
on file
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switching thresholds, assuming patients drop their pri-
mary therapy (oral semaglutide 14  mg or sitagliptin 
100 mg) upon adding insulin glargine, and independent 
cardiovascular effects. These scenarios were selected 
based on uncertainty around key inputs and assumptions 
(Table 4).
3  Results
3.1  Base‑Case Results
In a hypothetical 1 million lives plan, 13,162 patients 
would be eligible for oral semaglutide 14 mg in the sec-
ond-line T2DM population, with 1993 patients currently 
receiving sitagliptin 100 mg. If extrapolated to the US 
population, 4,378,040 patients would be eligible for oral 
semaglutide 14 mg, with 662,835 receiving sitagliptin 
100 mg (Table 3).
The average patient treated with the oral semaglutide 
14 mg pathway was estimated to incur $US39,997 in direct 
healthcare costs (medical and pharmacy) over 5 years, 
compared with $US23,436 for the average patient treated 
with the sitagliptin 100 mg pathway, an incremental cost 
per patient of $US16,562 (70.7% increase) (Table 5). Dia-
betes therapy costs represented the largest cost component 
in each pathway (86.6 and 76.7%, respectively), followed 
by cardiovascular, other direct medical, and hypoglyce-
mia costs. The cumulative incidence of clinical events was 
consistent across the two treatment strategies (Table 3 in 
the ESM). Results were driven by substantial differences 
in diabetes therapy costs. Over the 5-year time horizon, 
oral semaglutide 14  mg represented the bulk of these 
costs in the pathway, followed by basal insulin and met-
formin (85.1%, 14.8%, and 0.1%, respectively), whereas 
basal insulin constituted the majority of these costs in 
the sitagliptin 100  mg pathway (42.4% for sitagliptin 
100 mg, 57.4% for basal insulin, and 0.2% for metformin). 
While Oral semaglutide 14 mg is associated with a larger 
HbA1c decrease at treatment initiation (− 1.30 vs. − 0.88), 
the annual cost of oral semaglutide 14 mg is substantially 
higher than for sitagliptin 100 mg. Patients on sitagliptin 
100 mg add insulin glargine a year earlier than those on 
oral semaglutide 14 mg (year 4 vs. year 5), which results in 
a drop in HbA1c but higher diabetes therapy costs in year 
4. Minimal differences in the remaining costs were seen 
given (1) the relatively healthy patient profile of the popu-
lation, based on PIONEER 3 and VERTIS FACTORIAL, 
including low rates of cardiovascular disease (CVD) at 
baseline [22, 29] and (2) that the 5-year time horizon does 
not capture lifetime impacts of treatment, which may lead 
to greater differences between treatments. However, even 
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same third treatment in the sequence (metformin + insulin 
glargine + bolus insulin).
Extrapolating the model results to the population level, 
a hypothetical plan of 1 million lives over 5 years would 
incur a direct healthcare cost of $US46,698,940 (Table 4 
in the ESM). If oral semaglutide 14 mg is used for 14% of 
these patients (279 of 1993 patients on sitagliptin 100 mg), 
as presented in the Institute for Clinical and Economic 
Review report from their threshold analysis, the 5-year direct 
healthcare cost rises to $US51,319,140, an incremental cost 
increase of 9.9% ($US4,620,201, or $US0.08 per member 
per month [PMPM]) (Fig. 2). For every 10% market share 
that oral semaglutide 14 mg takes away from sitagliptin 
100 mg, the hypothetical payer would spend $US3,300,143 
(7.1%) more over 5 years. When extrapolating to the US 
population, this value increases to $US1,097,756,401 over 
5 years.
3.2  Scenario Results
Scenario analyses did not alter the conclusions of the base-
case analysis (Fig. 3). The cost of oral semaglutide 14 mg 
was the largest driver of results (scenarios 3–5), with dis-
counts leading to reduced diabetes therapy costs for oral 
semaglutide 14 mg over 5 years (incremental cost [% change 
vs. base case] − 40% discount: $US14,335 [− 13.4%]; 50% 
discount: $US9792 [− 40.9%]; 60% discount: $US5249 
[− 68.3%]). A threshold analysis found that a 71.6% WAC 
discount would be required for oral semaglutide 14 mg to 
generate 5-year per-patient costs equal to those of the sitag-
liptin 100 mg pathway (scenario 6).
Use of alternate HbA1c switching thresholds had a 
more notable impact on results (scenarios 7 and 8). A 7% 
switching threshold caused patients in both pathways to add 
insulin glargine at year 2 and to add bolus insulin and drop 
Fig. 2  5-year incremental 
budget impact analysis results 
for hypothetical 1 million lives 
plan. PMPM per member per 
month
Fig. 3  5-year per-patient costs—scenario results. Values in bold are 
the 5-year incremental difference per patient (% increase/decrease 
vs. the base case); Scenario 6 (WAC discount threshold analysis) is 
not included here as both the oral semaglutide 14 mg and sitagliptin 
100 mg costs per patient are equal. CV cardiovascular,  WAC  whole-
sale acquisition cost
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their primary therapy in year 5, leading to better clinical 
performance with lower HbA1c, along with higher diabetes 
therapy costs (incremental cost [% change vs. base case]: 
$US17,539 [5.9%]). Use of a 9% switching threshold caused 
patients to stay on their primary therapy for the duration of 
the analysis, resulting in an incremental cost per patient over 
5 years of $US21,619, a 30.5% increase from the base case.
When patients drop their primary therapy upon switch-
ing to insulin (scenario 9), diabetes therapy costs decrease 
in both pathways, with an incremental cost per patient over 
5 years of $US13,756 (16.9% reduction vs. the base case). 
The reduction is larger in the oral semaglutide 14 mg path-
way given the higher cost versus sitagliptin 100 mg.
The remaining scenarios had a limited impact on results. 
Use of the weighted treatment effect for oral semaglutide 
reduced the change in HbA1c from 1.30 to 1.11%, increas-
ing CVD and other direct medical costs while decreasing 
diabetes therapy costs for the oral semaglutide pathway, 
producing a total cost difference of $US16,585 over 5 years 
(0.1% increase from base case). Using the same insulin glar-
gine efficacy improved clinical performance, but as patients 
were only on this therapy for a year, the impact was minimal 
(incremental cost of $US16,552; 0.1% decrease from base 
case). Including the point estimates of the hazard ratios for 
cardiovascular events relative to placebo for the initial step 
in therapy only led to a 0.31% reduction in the incremental 
cost over 5 years for a patient treated with sitagliptin 100 mg 
versus oral semaglutide 14 mg compared with the base case.
4  Discussion
The analysis indicated that, for patients moving onto second-
line therapy, intensification with oral semaglutide 14 mg is 
more costly than sitagliptin 100 mg. For the average patient 
treated with sitagliptin 100 mg, a payer would spend an addi-
tional $US16,562 over 5 years if that patient was instead 
treated with oral semaglutide 14 mg. With oral semaglu-
tide 14 mg uptake ranging from 14 to 100%, the PMPM 
budget impact would be $US0.08–0.55, translating to 
$US1,536,858,962–10,977,564,012 for the US population.
These results were conservative for several reasons. 
First, the analysis assumed oral semaglutide patients would 
receive 14 mg. However, considering titration and the out-
comes in PIONEER 7, which applied a flexible dose-adjust-
ment approach to mimic individualized treatment in clinical 
practice, the actual treatment effect is likely to be lower [23]. 
The weighted oral semaglutide scenario accounted for this 
and produced a slightly higher budget impact compared with 
the base case (0.14%). Second, the HbA1c target can be 
higher for patients in worse health [10], and patient inertia 
could also delay switching, leaving patients on each treat-
ment step for longer.
The Institute for Clinical and Economic Review assessed 
the budget impact of oral semaglutide 14 mg versus different 
classes of treatments using their cost-effectiveness analysis 
(CEA) as the underlying engine, a similar approach to this 
analysis [35]. Like the CDM, their model was a patient-
level microsimulation using the UKPDS82 risk equations. 
The BIM considered a combined market basket of DPP-4i, 
GLP-1 RA, and SGLT-2i and found an incremental cost per 
patient of $US2600 for oral semaglutide when using net 
prices and considering prevalent patients. The analysis did 
not directly evaluate patients treated with sitagliptin 100 mg 
and their potential switch to oral semaglutide but found in 
the CEA that the intervention costs for oral semaglutide rep-
resented the bulk of cost differences ($US41,023, or 89% of 
total oral semaglutide costs).
A recently published study evaluated the cost per patient 
achieving HbA1c treatment target with oral semaglutide 
14 mg, concluding that oral semaglutide 14 mg brought 
patients to an HbA1c treatment target at a lower cost versus 
sitagliptin 100 mg over a 1-year time horizon [49]. The anal-
ysis considered four different efficacy metrics, which incor-
porated HbA1c and information on weight loss/gain and 
hypoglycemia. Additionally, the study included WAC costs 
and did not consider likely discounts as seen by US pay-
ers. The evaluation applied a simple metric by dividing the 
1-year treatment cost by the proportion of patients achieving 
target and calculated the relative difference between treat-
ments. The study translated key clinical outcomes into an 
easy-to-interpret cost/benefit metric based on the cost of the 
drug over 1 year compared with this analysis, which incor-
porated the modeling of future clinical impacts and treat-
ment sequences. Key limitations included the use of HbA1c 
as a way to simplify the impact of treatment on T2DM and 
the use of the most efficacious dose (14 mg), which likely 
overestimates oral semaglutide performance [23]. As only 
drug costs were included, the analysis was not comprehen-
sive, with results being very sensitive to both costs and time 
frame. Additionally, no scenario analyses were conducted 
outside of a probabilistic sensitivity analysis.
Our analysis provides an appropriate approach to evaluate 
the budget impact of oral semaglutide 14 mg as it incor-
porated treatment efficacy and disease management costs. 
Simulation models leveraging risk equations allow repre-
sentative disease progression modeling for a multifactorial 
condition such as T2DM. Treatment sequences are consid-
ered to reflect how therapies are used in real-world practice.
As with all modeling analyses, this analysis has limita-
tions that should be considered when interpreting the results. 
First, to best align with the source for treatment efficacy, 
the baseline cohort characteristics followed the PIONEER 
3 publication, with data gaps filled by using another clini-
cal trial for the same target population. Although data came 
from two sources, a comparison of baseline parameters 
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available from both studies indicated consistency in patient 
characteristics. Additionally, the studies included patients 
with T2DM with low rates of cardiovascular events, which 
may not reflect the real-world population. Second, PIO-
NEER 3 reported data for the three doses of oral semaglu-
tide, but the 14 mg arm was used to inform our base-case 
efficacy. PIONEER 7 showed that patients could not always 
up-titrate or tolerate the highest dose, and the weighted effi-
cacy scenario found a small cost increase versus the base 
case. Third, there is no direct comparison of oral semaglu-
tide 14 mg and sitagliptin 100 mg when they are used in 
combination with insulin glargine. Evidence is available for 
treatment efficacy and safety to compare metformin + sitag-
liptin 100 mg + insulin glargine versus metformin + insulin 
glargine among patients for whom dual therapy with met-
formin and sitagliptin 100 mg failed. However, no study 
with the desired sequence of therapy was available for oral 
semaglutide 14 mg. The total hypoglycemic event rate is 
higher with oral semaglutide 14 mg based on PIONEER 
3, so the assumption that the metformin + oral semaglutide 
14 mg + insulin glargine combination is associated with the 
same hypoglycemic event rate as metformin + sitagliptin 
100 mg + insulin glargine could skew the results in favor of 
oral semaglutide 14 mg. The basal insulin combination study 
for subcutaneous semaglutide was considered inappropriate 
for use in this analysis, and there is considerable difference 
between oral and subcutaneous semaglutide HbA1c effi-
cacy [31, 50]. Fourth, the cardiovascular impacts of T2DM 
therapies have garnered increased interest [10, 51–53]. 
Direct cardiovascular effect was not incorporated in the 
base case because of a lack of direct evidence between oral 
semaglutide 14 mg and sitagliptin 100 mg. However, both 
have demonstrated some cardiovascular protective effects 
in other trials, though with confidence intervals for key out-
comes overlapping. The scenario included in the analysis 
using hazard ratio point estimates versus placebo from the 
CVOTs found a minimal impact on model results [15, 16]. 
Even when the 95% confidence interval of the hazard ratios 
for oral semaglutide 14 mg and sitagliptin 100 mg is used 
in the analysis, the incremental cost over 5 years ranged 
from − 0.45 to 0.41% versus the base case. Additional evi-
dence is needed to allow more definitive conclusions on 
cardiovascular outcomes. Fifth, the impact of medication 
adherence was not included in this analysis. While clinical 
trial data are based on optimal adherence, studies show that 
adherence to oral diabetes therapies can range from 38 to 
93% based on different methodologies, with one meta-anal-
ysis estimating an adherence rate of 67.9% [54, 55]. No real-
world data are available on oral semaglutide adherence. Oral 
semaglutide is to be taken at least 30 min prior to first con-
sumption of food or water and was associated with higher 
rates of gastrointestinal adverse events than was sitagliptin 
100 mg [22, 56]. Given that both oral semaglutide 14 mg 
and sitagliptin 100 mg are oral treatments taken daily, adher-
ence was not considered in the analysis. Sixth, this analysis 
focused on two specific treatment pathways, where basal 
insulin was added in the second step in therapy. Given that 
T2DM requires a patient-centric approach, other treatments 
could be used in patients, with their own efficacy and cost 
outcomes. Given the limited data on specific combinations 
of treatment and the desired order of treatment addition, 
this study uses the best available evidence to represent a 
potential treatment pathway. Seventh, oral semaglutide may 
supplant other therapies in addition to sitagliptin, including 
injectable GLP-1 RAs; this analysis focused on sitagliptin 
100 mg because it is also an oral medication. Finally, the 
analysis makes simplifying assumptions when sizing the 
target population and estimating relative oral semaglutide 
14 mg uptake. However, these assumptions were tested in 
sensitivity analyses and, even assuming relatively low draw 
from sitagliptin 100 mg to oral semaglutide 14 mg, the over-
all budget impact for a payer will increase.
5  Conclusion
The results indicated that the increase in treatment cost with 
the use of oral semaglutide 14 mg outweighed the cost sav-
ings in other categories. With a 5-year incremental cost of 
$US16,562 per patient, oral semaglutide 14 mg increases the 
budget impact compared with sitagliptin 100 mg for patients 
with T2DM whose blood glucose level is not under control 
with metformin treatment. This conclusion held across a 
variety of scenario analyses.
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